vs
Side-by-side financial comparison of Origin Bancorp, Inc. (OBK) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $75.5M, roughly 1.4× PUMA BIOTECHNOLOGY, INC.). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 3.9%).
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
OBK vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $104.0M | $75.5M |
| Net Profit | $27.7M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 26.6% | — |
| Revenue YoY | — | 27.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.89 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.0M | — | ||
| Q4 25 | $103.4M | $75.5M | ||
| Q3 25 | $109.8M | $54.5M | ||
| Q2 25 | $83.5M | $52.4M | ||
| Q1 25 | $94.1M | $46.0M | ||
| Q4 24 | $78.3M | $59.1M | ||
| Q3 24 | $90.8M | $80.5M | ||
| Q2 24 | $96.4M | $47.1M |
| Q1 26 | $27.7M | — | ||
| Q4 25 | $29.5M | — | ||
| Q3 25 | $8.6M | $8.8M | ||
| Q2 25 | $14.6M | $5.9M | ||
| Q1 25 | $22.4M | $3.0M | ||
| Q4 24 | $14.3M | — | ||
| Q3 24 | $18.6M | $20.3M | ||
| Q2 24 | $21.0M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | — | — | ||
| Q4 25 | 36.2% | 22.7% | ||
| Q3 25 | 10.0% | 17.6% | ||
| Q2 25 | 22.3% | 12.7% | ||
| Q1 25 | 30.4% | 8.7% | ||
| Q4 24 | 23.0% | 22.6% | ||
| Q3 24 | 26.1% | 27.4% | ||
| Q2 24 | 27.7% | -4.6% |
| Q1 26 | 26.6% | — | ||
| Q4 25 | 28.5% | — | ||
| Q3 25 | 7.9% | 16.2% | ||
| Q2 25 | 17.5% | 11.2% | ||
| Q1 25 | 23.8% | 6.5% | ||
| Q4 24 | 18.2% | — | ||
| Q3 24 | 20.5% | 25.2% | ||
| Q2 24 | 21.8% | -9.6% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.95 | $0.26 | ||
| Q3 25 | $0.27 | $0.17 | ||
| Q2 25 | $0.47 | $0.12 | ||
| Q1 25 | $0.71 | $0.06 | ||
| Q4 24 | $0.45 | $0.40 | ||
| Q3 24 | $0.60 | $0.41 | ||
| Q2 24 | $0.67 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $1.3B | $130.3M |
| Total Assets | $10.2B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $424.2M | $97.5M | ||
| Q3 25 | $626.9M | $94.4M | ||
| Q2 25 | $334.1M | $96.0M | ||
| Q1 25 | $486.2M | $93.2M | ||
| Q4 24 | $470.2M | $101.0M | ||
| Q3 24 | $321.2M | $96.7M | ||
| Q2 24 | $288.1M | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.2B | $130.3M | ||
| Q3 25 | $1.2B | $115.3M | ||
| Q2 25 | $1.2B | $104.7M | ||
| Q1 25 | $1.2B | $97.1M | ||
| Q4 24 | $1.1B | $92.1M | ||
| Q3 24 | $1.1B | $71.1M | ||
| Q2 24 | $1.1B | $48.5M |
| Q1 26 | $10.2B | — | ||
| Q4 25 | $9.7B | $216.3M | ||
| Q3 25 | $9.8B | $202.9M | ||
| Q2 25 | $9.7B | $194.9M | ||
| Q1 25 | $9.8B | $196.2M | ||
| Q4 24 | $9.7B | $213.3M | ||
| Q3 24 | $10.0B | $220.7M | ||
| Q2 24 | $9.9B | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $158.9M | $14.4M | ||
| Q3 25 | $59.3M | $9.7M | ||
| Q2 25 | $20.6M | $14.1M | ||
| Q1 25 | $35.6M | $3.6M | ||
| Q4 24 | $108.5M | $15.6M | ||
| Q3 24 | $39.6M | $11.0M | ||
| Q2 24 | $11.9M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $151.1M | $14.4M | ||
| Q3 25 | $56.8M | $9.7M | ||
| Q2 25 | $19.6M | $14.1M | ||
| Q1 25 | $34.8M | $3.6M | ||
| Q4 24 | $86.4M | $15.6M | ||
| Q3 24 | $32.2M | $11.0M | ||
| Q2 24 | $6.5M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 146.0% | 19.1% | ||
| Q3 25 | 51.7% | 17.7% | ||
| Q2 25 | 23.5% | 26.8% | ||
| Q1 25 | 37.0% | 7.7% | ||
| Q4 24 | 110.3% | 26.4% | ||
| Q3 24 | 35.5% | 13.7% | ||
| Q2 24 | 6.8% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 0.0% | ||
| Q3 25 | 2.3% | 0.0% | ||
| Q2 25 | 1.2% | 0.0% | ||
| Q1 25 | 0.8% | 0.1% | ||
| Q4 24 | 28.1% | 0.0% | ||
| Q3 24 | 8.1% | 0.0% | ||
| Q2 24 | 5.6% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 5.38× | — | ||
| Q3 25 | 6.88× | 1.10× | ||
| Q2 25 | 1.41× | 2.41× | ||
| Q1 25 | 1.59× | 1.21× | ||
| Q4 24 | 7.60× | — | ||
| Q3 24 | 2.13× | 0.54× | ||
| Q2 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
PBYI
Segment breakdown not available.
